| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 41, 402-404, Copyright © 1975 by Endocrine Society
ARTICLES |
L Tseng and E Gurpide
Medroxyprogesterone acetate (Provera) was administered orally during 2- 4 days to women undergoing endometrial curettage during the follicular phase of the menstrual cycle. Estradiol (E2) receptor levels were estimated from the amounts of 2H-E2 tightly bound in nuclei after incubation of endometrial tissue with an excess of the labeled hormone. An average value (9 subjects) of 1.5 pmole E2/mg DNA +/- 0.7 (mean +1- SD) was found. This value is significantly lower than the average E2 receptor levels in proliferative endometrium of untreated subjects (3.2 +/- 1.3, n = 33) and equals the level observed in the early secretory phase (1.5 +/- 0.5, n = 5). These results indicate that one of the progestin effects on human endometrium is the reduction of E2 receptor levels.
This article has been cited by other articles:
 |
|
 |
|
  R. Pilka, I. Oborna, V. Lichnovsky, P. Havelka, H. Fingerova, P. Eriksson, S. Hansson, and B. Casslen Endometrial expression of the estrogen-sensitive genes MMP-26 and TIMP-4 is altered by a substitution protocol without down-regulation in IVF patients Hum. Reprod., December 1, 2006; 21(12): 3146 - 3156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yang, Z. Fang, B. Gurates, M. Tamura, J. Miller, K. Ferrer, and S. E. Bulun Stromal PRs Mediate Induction of 17{beta}-Hydroxysteroid Dehydrogenase Type 2 Expression in Human Endometrial Epithelium: A Paracrine Mechanism for Inactivation Of E2 Mol. Endocrinol., December 1, 2001; 15(12): 2093 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Strohsnitter, K. L. Noller, R. N. Hoover, S. J. Robboy, J. R. Palmer, L. Titus-Ernstoff, R. H. Kaufman, E. Adam, A. L. Herbst, and E. E. Hatch Cancer Risk in Men Exposed In Utero to Diethylstilbestrol J Natl Cancer Inst, April 4, 2001; 93(7): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weiderpass, H.-O. Adami, J. A. Baron, C. Magnusson, R. Bergstrom, A. Lindgren, N. Correia, and I. Persson Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins J Natl Cancer Inst, July 7, 1999; 91(13): 1131 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Abrams, J. Aisner, C. Cirrincione, D. A. Berry, H. B. Muss, M. R. Cooper, I. C. Henderson, L. Panasci, J. Kirshner, J. Ellerton, et al. Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741 J. Clin. Oncol., January 1, 1999; 17(1): 64 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Giangrande, G. Pollio, and D. P. McDonnell Mapping and Characterization of the Functional Domains Responsible for the Differential Activity of the A and B Isoforms of the Human Progesterone Receptor J. Biol. Chem., December 26, 1997; 272(52): 32889 - 32900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Graham and C. L. Clarke Physiological Action of Progesterone in Target Tissues Endocr. Rev., August 1, 1997; 18(4): 502 - 519. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
